← Back to Search

[oxoisoindolin-14C]ARV-471 for Healthy Subjects

Phase 1
Waitlist Available
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up time the participant provides informed consent through and including follow-up contact occurring 28 to 35 calendar days after the last administration of the study intervention.
Awards & highlights
No Placebo-Only Group

Summary

This trial tests how the body handles ARV-471, a liquid medicine taken by mouth, in healthy adults who cannot have children.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~time the participant provides informed consent through and including follow-up contact occurring 28 to 35 calendar days after the last administration of the study intervention.
This trial's timeline: 3 weeks for screening, Varies for treatment, and time the participant provides informed consent through and including follow-up contact occurring 28 to 35 calendar days after the last administration of the study intervention. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Number of Participants With Abnormalities in Physical Examinations
Number of Participants With Clinical Laboratory Abnormalities
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
+2 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: [phenyl-14C]ARV-471Experimental Treatment1 Intervention
\[phenyl-14C\]ARV-471 is administered as a single dose
Group II: [oxoisoindolin-14C]ARV-471Experimental Treatment1 Intervention
\[oxoisoindolin-14C\]ARV-471 is administered as a single dose
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
[phenyl-14C]ARV-471
2023
Completed Phase 1
~20
[oxoisoindolin-14C]ARV-471
2023
Completed Phase 1
~20

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

PfizerLead Sponsor
4,658 Previous Clinical Trials
17,877,271 Total Patients Enrolled
Arvinas Estrogen Receptor, Inc.Industry Sponsor
18 Previous Clinical Trials
2,370 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,544 Previous Clinical Trials
14,918,447 Total Patients Enrolled
~5 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top